Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries.
Velpandian
T
T
Sharma
C
C
Garg
S P
SP
Mandal
S
S
Ghose
S
S
D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000592:standards*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D003906:Developing Countries; D004305:Dose-Response Relationship, Drug; D054796:Drug Dosage Calculations; D004349:Drug Packaging / Q000191:economics* / Q000592:standards*; D006801:Humans; D012164:Retinal Diseases / Q000188:drug therapy* / Q000191:economics
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab